Latest Tax Incentives News

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.

Identitii Limited advances its BNDRY platform with new agreements targeting hospitality and payments sectors, appoints Tim Phillipps as Executive Chair, and reports stable cash flow amid ongoing patent litigation.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Critica Limited has declared a maiden Inferred Mineral Resource Estimate for its Jupiter Project, establishing it as Australia’s largest and highest-grade clay-hosted rare earth deposit. Early metallurgical testwork shows promising beneficiation results, positioning the company as a strategic player in the rare earths sector.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Ausmon Resources Limited has launched a Share Purchase Plan offering shareholders shares at an 8.6% discount, with potential tax credits for Australian investors. The move aims to strengthen the company’s balance sheet and fund exploration activities.

SG Fleet Group reported robust first-half 2025 results, driven by strong delivery volumes and revenue growth across Australia, New Zealand, and the UK, despite ongoing pressures in the used vehicle market.

SG Fleet Group reported a solid $41.1 million NPAT for the first half of 2025, driven by strong disposal volumes and fleet growth across Australia, New Zealand, and the UK. While profit dipped from last year, the company anticipates normalization in the second half.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Chalice Mining has achieved a major metallurgical breakthrough at its Gonneville Project, enabling the production of saleable copper and nickel concentrates from low-grade ores without costly hydrometallurgical processing. This innovation promises to significantly reduce capital and operating costs while improving project margins.